Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:48 AM ET 8-K
Financial Results Enviri Corp NVRI

Enviri Financial Results

Enviri Corporation reported Q3 2026 revenues of $325 million and GAAP income from continuing operations of $6 million. The company raised its full-year Adjusted EBITDA outlook for its Harsco Environmental and Harsco Rail segments following strong quarterly performance and the execution of an agreement with Deutsche Bahn that released the Rail segment from ETO contract obligations.

Term
Q3 2026

“We experienced continued momentum across both of our businesses in the third quarter, with Enviri delivering adjusted earnings growth of more than 20% for the second consecutive quarter and achieving better than anticipated results.”

Russell Hochman, Enviri President and CEO

“Both businesses, in fact, reported their highest quarterly earnings in approximately two years, with this performance supported by strong operational execution. Based on these results, we have raised our full-year Adjusted EBITDA outlook.”

Russell Hochman, Enviri President and CEO
7:47 AM ET 10-Q
Financial Results Distribution Solutions Group, Inc. DSGR

Distribution Solutions Group Q3 2026 Results: Net Income $8.89M, Up 37.8% YoY

Distribution Solutions Group reported total assets of $1.88 billion as of September 30, 2026, with a significant increase in accounts receivable and inventories compared to year-end 2025. The company is currently navigating a proposed merger and maintains a substantial debt load of approximately $758.6 million.

Key figure
Net income $8.89M · +37.8% YoY
7:47 AM ET 8-K
Financial Results Viatris Inc VTRS

Viatris Financial Results

Viatris reported Q3 2026 total revenues of $3.75 billion and raised its full-year 2026 financial guidance midpoints across all metrics. The company reported a GAAP net loss of $325.3 million, primarily driven by operational momentum in higher-margin businesses and progress in its innovative medicines strategy, including the pending acquisition of Pacira BioSciences.

Term
Q3 2026

“Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business. Momentum across key areas of our base business, progress in our pipeline and the benefits of our enterprise-wide strategic review continue to strengthen our company.”

Scott A. Smith, CEO, Viatris

“We are very pleased with the operational momentum across our higher-margin businesses and continued focus on cost discipline, which led to strong overall third-quarter results. Based on this performance and our confidence in the outlook for the rest of the year, we are once again raising the midpoints of our financial guidance ranges across all key metrics.”

Paul Campbell, Interim CFO, Chief Accounting Officer & Corporate Controller, Viatris
7:46 AM ET 10-Q
Financial Results Pyxis Oncology, Inc. PYXS

Pyxis Oncology Q3 2026 Results: Net Loss of $20M, Loss Narrows

Pyxis Oncology reported a net loss of $68.6 million for the nine months ended September 30, 2026, compared to $61.5 million in the prior year. The company remains in the clinical stage, heavily dependent on its lead product candidate micvotabart pelidotin (MICVO), and recently completed a private placement of common stock to raise approximately $48.3 million.

Key figure
Net loss $20M
7:45 AM ET 8-K
Financial Results Steven Madden, Ltd. SHOO

Steven Madden Financial Results

Steven Madden reported a 15.7% increase in Q3 2026 revenue to $772.6 million, driven by strong performance in the wholesale business and the Steve Madden brand. The company also declared a quarterly cash dividend of $0.21 per share and raised its full-year revenue and earnings outlook.

Term
Q3 2026

“We delivered an outstanding third quarter, with strong growth across our brands and channels. The Steve Madden brand was a particular highlight, as our trend-right product assortments and compelling marketing continue to resonate with consumers and drive strong momentum.”

Edward Rosenfeld, Chairman and Chief Executive Officer

“Based on our strong year-to-date results and the continued momentum we see in the business, we are raising our revenue and Adjusted diluted earnings per share outlook for the year.”

Edward Rosenfeld, Chairman and Chief Executive Officer
7:45 AM ET 8-K
Financial Results Cars.com Inc. CARS

Cars.com Financial Results

Cars.com reported Q3 2026 revenue of $181.9 million and a 113% year-over-year increase in net income to $16.3 million. The company highlighted momentum in its Marketplace segment, including the launch of a new self-service Starter package and reaching 12% adoption for its Premium+ tier.

Term
Q3 2026

“Our third quarter results reinforced the growing strength of our core, scaled Marketplace. We once again grew Marketplace customers, reached another milestone in Premium+ package adoption, and also launched our first ever self-service subscription designed to meet the needs of local independent dealers. These outcomes flow directly from fundamental improvements to our operating model throughout 2026 that span our focus areas of product innovation, process efficiency, and organizational talent.”

Tobias Hartmann, Chief Executive Officer of Cars.com, Inc.
7:44 AM ET 8-K
Financial Results ACM Research, Inc. ACMR

ACM Research Financial Results

ACM Research reported Q3 2026 revenue of $367.7 million, a 37% increase year-over-year, driven by robust demand for ECP and advanced packaging technologies. The company raised its full-year 2026 revenue guidance to exceed the upper end of its previous range and announced that its second Lingang manufacturing building will double its floor space starting in Q4.

Term
Q3 2026

“We delivered another strong quarter, with revenue increasing 37% and shipments growing 31% year over year. Demand for our differentiated technologies remains robust across our expanding product portfolio, with ECP and advanced packaging leading our growth, and our cleaning category returning to year-over-year growth. The second building of our Lingang manufacturing facility is coming online in the fourth quarter, doubling our manufacturing floor space to support future growth.”

Dr. David Wang, President and Chief Executive Officer of ACM

“We are raising our 2026 revenue outlook, and now expect revenue above the upper end of our prior range. Looking ahead, we believe our broadening and differentiated product portfolio, our global footprint, and our customer relationships position us to capture new market opportunities and deliver sustainable long-term growth.”

Dr. David Wang, President and Chief Executive Officer of ACM
7:44 AM ET 8-K
Financial Results Gibraltar Industries, Inc. ROCK

Gibraltar Industries Financial Results

Gibraltar Industries reported Q3 2026 financial results, featuring a 54% increase in net sales driven by the OmniMax acquisition and 3.1% organic growth in its Residential segment. The company announced the divestiture of its Infrastructure business for $208 million and raised its 2026 cost synergy commitment to $36.5 million while adjusting full-year guidance due to a slower residential market outlook.

Term
Q3 2026

“Our residential business delivered solid revenue and margin performance in an end market that declined 13% in the quarter, slowing more than 2.5 times our expectation going into the quarter. Despite sector weakness, our Residential business generated organic growth of 3.1% and delivered 18.9% adjusted EBITDA margin.”

Bill Bosway, Chairman and CEO

“We remained focused on our core strategic priorities – simplifying the portfolio, strengthening the balance sheet, integrating OmniMax, and optimizing the Residential business.”

Bill Bosway, Chairman and CEO
7:42 AM ET 8-K
Financial Results Sabre Corp SABR

Sabre Financial Results

Sabre reported Q3 2026 revenue of $738 million, a 3% increase year-over-year, driven by growth in its Marketplace and Airline Technology segments. The company raised its full-year 2026 Pro Forma Adjusted EBITDA and Free Cash Flow guidance for the second consecutive quarter while completing a debt refinancing that extended maturities to 2032.

Term
Q3 2026

“Sabre delivered strong third-quarter results, reflecting continued execution of our strategy and growing momentum across our business. We achieved our fifth consecutive quarter of double-digit year-on-year growth in Normalized Adjusted EBITDA and, for the second consecutive quarter, we are raising our full-year 2026 guidance for Pro Forma Adjusted EBITDA and Free Cash Flow.”

Kurt Ekert, president and CEO

“We are seeing expanded profitability as we drive consistent revenue growth, coupled with disciplined cost management. Looking ahead, we are confident in our ability to achieve our increased full-year 2026 guidance and expect to generate positive free cash flow in 2027, providing greater financial flexibility to capitalize on the opportunities ahead and drive long-term shareholder value.”

Kurt Ekert, president and CEO
7:41 AM ET 8-K
Financial Results Kelly Services Inc KELYA

Kelly Services Financial Results

Kelly Services reported Q3 2026 revenue of $0.9 billion, a 0.8% year-over-year decrease, though underlying revenue grew 2.3% when excluding discrete impacts. The company achieved adjusted EBITDA of $21.3 million with a margin of 2.3%, reflecting improved gross profit rates and continued SG&A discipline.

Term
Q3 2026

“In the third quarter, we delivered results above the midpoint of our guidance, driven by meaningful progress on our growth and efficiency initiatives along with increasingly constructive demand trends. Year-over-year revenue improved sequentially for a third consecutive quarter, and we drove adjusted EBITDA margin expansion over the prior year period. Our performance reflects positive operational momentum across much of our portfolio, as ETM pivoted to positive year-over-year revenue growth in the quarter and SET delivered another quarter of sequential revenue improvement. We remain well positioned to capitalize on increasing demand while continuing to drive margin expansion and long-term value creation.”

Chris Layden, chief executive officer
7:41 AM ET 8-K
Financial Results Lantheus Holdings, Inc. LNTH

Lantheus Holdings Financial Results

Lantheus Holdings reported Q3 2026 financial results with worldwide revenue of $389.9 million and adjusted EPS of $1.68. The company also highlighted the pending $8.0 billion acquisition by Curium and the recent FDA approvals of TAUKLARIFY and BRAVNETSA. Due to the pending merger, the company has suspended its full-year 2026 financial guidance.

7:40 AM ET 10-Q
Financial Results Intensity Therapeutics, Inc. INTS ▶ Call

Intensity Therapeutics Q3 2026 Results: Net Loss of $3.54M, Loss Widens

Intensity Therapeutics reported a net loss of $9.0 million for the nine months ended September 30, 2026, compared to $8.6 million in the prior year period. The company's cash position decreased to $8.5 million from $11.9 million at year-end 2025, primarily due to ongoing research and development expenses for its lead drug candidate, INT230-6.

Key figure
Net loss $3.54M
7:40 AM ET 8-K
Financial Results Distribution Solutions Group, Inc. DSGR

Distribution Solutions Group Financial Results

Distribution Solutions Group reported third quarter 2026 revenue of $573.6 million, a 10.7% increase year-over-year driven by 9.2% organic growth. Net income rose to $8.9 million, or $0.19 per diluted share, while Adjusted EBITDA margin improved 50 basis points to 9.9%. The results were supported by average daily sales improvements across all business units and a small contribution from the American Fasteners acquisition.

Term
Q3 2026
7:40 AM ET 8-K
Business Update Enovix Corp ENVX

Enovix Business Update

Enovix announced a cost reduction plan involving a reduction of approximately 220 positions (23% of its workforce) to save $8.5 million annually. The company is rebalancing its operations to focus on its South Korean plant, where it is investing $19 million to double capacity for drone and defense batteries to meet a $216 million pipeline.

7:40 AM ET 8-K
Financial Results Pyxis Oncology, Inc. PYXS

Pyxis Oncology Financial Results

Pyxis Oncology reported financial results for the third quarter of 2026, ending the period with $114.3 million in cash and equivalents. The company highlighted progress on its lead candidate, micvotabart pelidotin (MICVO), including alignment with the FDA and EMA on the design of a global Phase 3 trial in head and neck cancer planned for mid-2027.

Term
Q3 2026

“The September monotherapy data reinforce our confidence in MICVO’s potential to serve a significant population of patients with previously treated recurrent/metastatic head and neck cancer. We have aligned with feedback received from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on the design of the global Phase 3 Headliner trial and plan to initiate it in mid-2027, with FDA feedback on dose selection expected in the first quarter of 2027.”

Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology
7:39 AM ET 8-K
Leadership Change Gibraltar Industries, Inc. ROCK

Gibraltar Industries Leadership Change

Joseph A. Lovechio resigned as Vice President and CFO of Gibraltar Industries effective November 20, 2026, to pursue another opportunity. The company appointed Jeffrey J. Watorek, currently VP and Treasurer, as Interim CFO and Lori Rizzo as principal accounting officer while it conducts a search for a permanent successor.

7:38 AM ET 8-K
Financial Results Teads Holding Co. TEAD

Teads Holding Financial Results

Teads Holding Co. reported Q3 2026 financial results with revenue of $235.1 million, a 26% year-over-year decline, and a net loss of $325.5 million. Alongside the results, the company announced the appointment of Michael Coyle as Chief Financial Officer, effective November 11, 2026, succeeding Jason B. Kiviat.

Term
Q3 2026

“In the third quarter, our Connected TV revenue grew 37% year-over-year, outperforming the broader market through our leading position on the CTV HomeScreen — the front door to the living-room experience.”

David Kostman, CEO of Teads

“Like many companies across our sector, we are navigating the significant headwinds currently impacting the open internet, and we are using this moment to focus on driving broader adoption of our Enterprise omnichannel offerings. We are seeing some improvement in trends in the early part of the fourth quarter and are taking decisive and appropriate actions to improve our revenue trajectory, optimize our cost structure, and strengthen our balance sheet”

David Kostman, CEO of Teads
7:38 AM ET 10-Q
Financial Results Akebia Therapeutics, Inc. AKBA

Akebia Therapeutics Q3 2026 Results: Net Loss of $14.4M

Akebia Therapeutics continues to face significant financial risks, including a history of losses and the need for substantial additional capital to fund operations. The company's business remains heavily dependent on the commercial success of Auryxia and Vafseo, while facing potential delisting from Nasdaq if compliance requirements are not met.

Key figure
Net loss $14.4M
7:37 AM ET 8-K
Stock Buyback Alnylam Pharmaceuticals, Inc. ALNY

Alnylam Pharmaceuticals Announces $1B Stock Buyback

Alnylam Pharmaceuticals announced that its Board of Directors authorized a new $1.0 billion share repurchase program. The company expects to repurchase approximately $500 million of its common stock by the end of 2026, with the remaining balance planned for 2027. Additionally, the company disclosed that Tolga Tanguler will depart from his role as Executive Vice President and Chief Commercialization Officer in December 2026.

Value
$1B
7:37 AM ET Form 4
Insider Buying Crh Public Ltd Co CRH

Crh Public Ltd Insider Siobhan Talbot Buys $189K of Stock

Siobhan Talbot bought 2,000 shares of Crh Public Ltd Co at $94.63 a share, worth $189K in total on Nov 3, 2026. Shares held after the trade: 10,507 (+23.5%).

Value
$189K
Shares
2,000
Price
$94.63
Holding change
+23.5%
Trade date
Nov 3, 2026
7:37 AM ET 10-Q
Financial Results SAB Biotherapeutics, Inc. SABS

SAB Biotherapeutics Q3 2026 Results: Net Loss of $22.3M

SAB Biotherapeutics reported a net loss of $22.3 million for the third quarter of 2026, compared to a net income of $45.4 million in the prior year period, primarily due to a significant decrease in the non-cash gain from the change in fair value of warrant liabilities. Operating expenses increased substantially to $25.9 million as the company ramped up research and development activities.

Key figure
Net loss $22.3M
7:36 AM ET 10-Q
Financial Results Arrow Electronics, Inc. ARW ▶ Call

Arrow Electronics Q3 2026 Results: Net Income $318M, Up 191.6% YoY

Arrow Electronics reported a significant increase in sales to $10.72 billion for the quarter ended October 3, 2026, compared to $7.71 billion in the prior-year period. Consolidated net income rose to $318.5 million, driven by strong performance in its Global Components and Global ECS segments, while the company maintained a robust balance sheet with total assets of $45.05 billion.

Key figure
Net income $318M · +191.6% YoY
7:36 AM ET 8-K
Financial Results Payoneer Global Inc. PAYO

Payoneer Global Financial Results

Payoneer Global Inc. reported third quarter 2026 financial results, featuring 2% revenue growth to $276.9 million and a 13% increase in total volume to $25.3 billion. The company highlighted significant momentum in its B2B segment, where volume grew 59% year-over-year, and noted that shareholders approved the pending merger with Nuvei in September 2026.

“Payoneer’s Q3 results show our upmarket strategy is working: B2B volume growth accelerated to 59% year-over-year, ARPU ex. interest expanded 20%+ year-over-year for a 9th consecutive quarter, and the percentage of our revenue from larger customers continues to grow.”

John Caplan, Chief Executive Officer

“We continue to work towards a targeted mid-2027 close of the Nuvei transaction. We received shareholder approval in September and are making progress with obtaining necessary regulatory approvals.”

John Caplan, Chief Executive Officer
7:35 AM ET 8-K
Financial Results Dyne Therapeutics, Inc. DYN

Dyne Therapeutics Financial Results

Dyne Therapeutics reported Q3 2026 financial results, highlighting a cash position of $684.1 million to support operations into late 2026. The company is preparing for a potential Q1 2027 U.S. launch of z-rostudirsen for DMD, which is currently under FDA priority review with a PDUFA date of January 21, 2027.

Term
Q3 2026

“As we work toward potential commercialization, we are investing across multiple programs with the goal of unlocking the full value of our FORCE platform. This includes preparations for the potential U.S. launch of z-rostudirsen for exon 51 DMD, if approved, and topline data from the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1, both expected in the first quarter of 2027.”

John Cox, president and chief executive officer of Dyne
7:35 AM ET 8-K
Financial Results Advanced Flower Capital Inc. AFCG

Advanced Flower Capital Financial Results

Advanced Flower Capital Inc. reported its third quarter 2026 financial results, highlighting a GAAP net investment income of $3.5 million and a net asset value (NAV) per share of $8.55. The company also repurchased approximately $1.0 million of its common stock during the quarter as part of its $5.0 million share repurchase program.

“AFC earned net investment income of $0.16 per share and grew NAV per share by $0.30 to $8.55. During the quarter, we repurchased approximately $1.0 million of our shares at roughly a 58% discount to NAV, adding $0.06 per share to NAV and bringing year-to-date accretion to $0.24. We will continue to allocate capital where it earns the best risk-adjusted return.”

Dan Neville, Chief Executive Officer
7:35 AM ET 10-Q
Financial Results Cabaletta Bio, Inc. CABA

Cabaletta Bio Q3 2026 Results: Net Loss of $53.1M, Loss Widens

Cabaletta Bio is a late-stage clinical biotechnology company focused on autoimmune diseases, specifically advancing its Phase 1/2 RESET clinical trials for rese-cel. As of October 30, 2026, the company reported 215,720,392 shares of common stock outstanding and continues to incur significant losses to fund its R&D and manufacturing partnerships with Lonza and Cellares.

Key figure
Net loss $53.1M
7:34 AM ET 10-Q
Financial Results Collegium Pharmaceutical, Inc COLL

Collegium Pharmaceutical Q3 2026 Results: Net Income $21.8M, Down 30.9% YoY

Collegium Pharmaceutical reported net income of $21.8 million for the third quarter of 2026, a decrease from $31.5 million in the prior year period, despite a slight increase in product revenues to $216.3 million. The company completed the acquisition of Azstarys during the nine-month period, contributing to a significant increase in total assets to $2.1 billion and a rise in operating expenses due to higher selling, general, and administrative costs.

Key figure
Net income $21.8M · -30.9% YoY
7:34 AM ET 10-Q
Financial Results Lucky Strike Entertainment Corp LUCK

Lucky Strike Entertainment Q1 2026 Results: Net Loss of $25.7M, Loss Widens

Lucky Strike Entertainment Corp reported total revenues of $302.6 million for the quarter ended September 27, 2026, a slight increase from $292.3 million in the prior year. However, the company saw its net loss widen to $25.7 million compared to $13.8 million previously, primarily driven by higher income tax expenses and increased selling, general, and administrative costs.

Key figure
Net loss $25.7M
7:34 AM ET 8-K
Financial Results Macom Technology Solutions Holdings, Inc. MTSI

Macom Technology Solutions Holdings Financial Results

MACOM reported record fiscal fourth quarter revenue of $424.8 million, up 62.7% year-over-year, and full-year revenue of $1.33 billion. The company achieved significant profitability improvements with fiscal year GAAP net income of $335.3 million compared to a net loss in the prior year. Management provided strong guidance for the first quarter of fiscal 2027, expecting continued revenue growth and margin expansion.

Term
FY2026

“We had a strong fiscal year 2026 and look forward to continued growth in fiscal 2027”

Stephen G. Daly, President and Chief Executive Officer
7:33 AM ET 8-K
Financial Results Sphere Entertainment Co. SPHR

Sphere Entertainment Financial Results

Sphere Entertainment reported Q3 2026 revenues of $274.3 million, a 4% increase year-over-year, driven by growth in the Sphere segment. The company reported an operating loss of $240.6 million, primarily due to results at MSG Networks, while adjusted operating income rose 8% to $39.2 million.

Term
Q3 2026

“With today’s results, our Sphere segment remains on track to deliver substantial growth this calendar year. Looking ahead, we continue to make progress on our long-term vision for Sphere, including a global network of venues and a growing slate of original content.”

James L. Dolan, Executive Chairman and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.